|Bid||29.39 x 110000|
|Ask||29.40 x 16000|
|Day's Range||29.36 - 29.56|
|52 Week Range||20.04 - 30.55|
|Beta (5Y Monthly)||1.38|
|PE Ratio (TTM)||29.43|
|Earnings Date||Aug 05, 2021|
|Forward Dividend & Yield||1.15 (3.97%)|
|Ex-Dividend Date||Jun 03, 2021|
|1y Target Est||34.47|
German chemicals group Evonik Industries has started delivering a key ingredient for the Pfizer/BioNTech COVID-19 vaccine ahead of time, in a boost for the pair's efforts to ramp up production. Evonik said on Thursday it had set up lipid production at its site in Hanau, Germany, in eight weeks, much more quickly than expected, and started to deliver the first batches to be used in the vaccine. The main ingredient in the Pfizer/BioNTech vaccine - the messenger RNA (mRNA) that helps prompt an immune response against the coronavirus - must be packaged inside lipid nanoparticles to protect the fragile material from degradation once it has been injected into people.
Rating Action: Moody's downgrades Evonik to Baa2, changes outlook to stableGlobal Credit Research - 20 Apr 2021Frankfurt am Main, April 20, 2021 -- Moody's Investors Service ("Moody's") today downgraded to Baa2 from Baa1 the long term issuer rating and senior unsecured bond ratings of Evonik Industries AG ("Evonik"). Moody's also downgraded to Baa2 from Baa1 the rating on the senior unsecured bonds of Evonik Finance B.V.. The rating outlook on both entities was changed to stable from negative.A full list of affected ratings can be found at the end of this press release.RATINGS RATIONALEThe downgrade of Evonik's long-term issuer rating to Baa2 reflects Moody's-adjusted gross financial leverage with debt/EBITDA that has been above 3.0x since 2016 and low Moody's-adjusted free cash flow (FCF) generation -- average of around E109 million in the 2016-2020 period -- that limits the ability to deleverage.
Vaccine makers are shoring up theirsupply of a critical raw material in "messenger RNA" vaccines:the lipid molecules that help deliver the genetic RNA materialinto cells. Manufacturers are under pressure to increase production ofCOVID-19 vaccines as infections from the pandemic approach 110million people. But the supply effort has gotten off to a slow start, andvaccine makers still face multiple potential bottlenecks,including a tight supply of lipids used in mRNA vaccines fromPfizer Inc and German partner BioNTech, aswell as Moderna Inc.